1 / 10

Pharmacovigilance Market to Project 9.7% CAGR from 2014 to 2020 | Hexa Research

Pharmacovigilance Market Analysis By Clinical Trial Phases, By Type Of Service Providers (In House, Contract Outsourcing), Market Size, Application Analysis, Regional Outlook, Competitive Strategies And Forecasts To 2020

Carrol
Download Presentation

Pharmacovigilance Market to Project 9.7% CAGR from 2014 to 2020 | Hexa Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Your Catalyst To a Lucrative Business Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Growth and Forecast to 2020 - Hexa Research “Increasing rate of adverse drug reaction coupled with rising drug consumption globally is anticipated to propel the market growth for pharmacovigilance market.” The Global Pharmacovigilance Market is expected to grow at a CAGR nearly 9.7% during the forecast period (2014 to 2020). This industry was valued at approximately USD 2410 million in 2013. High incidence of adverse drug reaction (ADR) and stringent regulatory norms pertaining to drug safety drive the overall industry. Pharmacovigilance, also known as drug safety involves testing the effects of medical drugs once these have been approved & licensed for use. This is done basically to identify & evaluate adverse reactions that had gone unreported in the past. It utilizes pharmacological science that helps in the collection, assessment, detection, monitoring, and prevention of drug reactions after pharmaceutical drugs have been consumed. Issues of drug toxicity, rising cases of chronic ailments, and an ever-expanding geriatric population cumulatively impact overall industry demand. Browse Details of Report@ https://www.hexaresearch.com/research-report/pharmacovigilance-industry Follow Us:

  2. Your Catalyst To a Lucrative Business The worldwide pharmacological market is categorized on the basis of clinical trials, types of methods, service types, and geographies. As per clinical trial phases, the segments are preclinical, phase 0, phases I, II, III, and IV. The usage rate was by far the highest for phase IV in 2013. Before getting the nod from regulatory authorities, phase IV needs to necessarily clear the following vital stages: quality inspection, efficacy test, and safety of use. Data gathered during the post phase III stage is highly reliable & widely accepted. The phase IV trials market holds the largest share, closely followed by the phase III market. As against phase I & II, phase III witnesses maximum drug safety clearances. Based on types of methods, the global Pharmacovigilance Market is categorized into intensified ADR reporting, cohort event monitoring, target reporting, EHR monitoring, and spontaneous reporting. The EHR monitoring segment may expand robustly during the forecast period. This market is fueled by the growing trend of automation & digitalization in healthcare. EHR devices facilitate effective communications between doctors and patients owing to efficient data sharing capabilities electronically. House manufacturing and contract outsourcing are two types of services in the pharmacovigilance market. Contractual outsourcing led the industry in 2013. Due to globalization, developed countries can manufacture goods & services at affordable costs because of outsourcing. Outsourcing leads to lower production failures and helps overcome the problem of depleting stocks. It could even lower fixed costs, facilitate effective resource management, mitigate risks, and reduce upfront investments. Geographically, the global pharmacovigilance industry is divided into Europe, North America, and Asia Pacific. North America dominated the industry in 2013. Implementation of drug safety regulatory norms by FDA and substantial R&D investments are key regional drivers. Asia Pacific could expand robustly during the forecast period because of availability of cheap labor and widespread awareness about ADR. This region offers several lucrative opportunities for further market progress. Prominent competitors in the worldwide pharmacovigilance market are Janssen Research & Development, United BioSource Corporation, Cognizant Technology Solutions Corporation, Boehringer Ingelheim Gmbh, and Bristol-Myers Squibb. Most companies engage in business ventures, such as mergers and acquisitions in order to gain higher market shares. The life sciences industry is a rapidly developing one. Advanced automation is gaining much importance in this industry as it is in the others. While most life sciences companies aim at launching products rapidly & cost effectively, they also need to ensure other key aspects. The devices & drugs being produced, besides fulfilling patient needs, must lead to better outcomes in the short & long term. A number of life sciences Follow Us:

  3. Your Catalyst To a Lucrative Business organizations have adopted automation for modernization of core enterprise systems. These have proved useful in many ways. In pharmacovigilance, it plays a key role in quality measurement, quantitative studies, customer service, data capture, and cognitive learning for medical report analysis, and others. Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/medical-devices- industry Follow Us:

  4. Your Catalyst To a Lucrative Business Table of Content of Pharmacovigilance Market Chapter 1. Executive Summary 1.1. Pharmacovigilance - Industry Summary and Critical Success Factors (CSFs) Chapter 2. Pharmacovigilance Industry Outlook 2.1. Market Segmentation 2.2. Market Size and Growth Prospects 2.3. Pharmacovigilance - Market dynamics 2.3.1. Market Driver Analysis 2.3.2. Market Restraint Analysis 2.4. Key Opportunities Prioritized 2.5. Pharmacovigilance - PESTEL Analysis 2.6. Pharmacovigilance Company Market Share Analysis, 2013 Chapter 3. Pharmacovigilance Clinical Trial Phase Outlook 3.1. Pharmacovigilance market share, by clinical trial phase, 2013 & 2020 3.2. Preclinical 3.2.1. Preclinical Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.3. Phase 0 3.3.1. Phase 0 Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.4. Phase I 3.4.1. Phase I Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.5. Phase II 3.5.1. Phase II Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.6. Phase III 3.6.1. Phase III Market Estimates and Forecasts, 2012 - 2020 (USD Million) 3.7. Phase IV 3.7.1. Phase IV Market Estimates and Forecasts, 2012 - 2020 (USD Million) Chapter 4. Pharmacovigilance Type of Service Provider Outlook 4.1. Pharmacovigilance market share, by type of service provider, 2013 & 2020 4.2. In- House 4.2.1. In-House Market Estimates and Forecasts, 2012 - 2020 (USD Million) 4.3. Contract Outsourcing 4.3.1. Contract Outsourcing Market Estimates and Forecasts, 2012 - 2020 (USD Million) Follow Us:

  5. Your Catalyst To a Lucrative Business Chapter 5. Pharmacovigilance Regional Outlook 5.1. Pharmacovigilance market share by region, 2012 & 2020 5.2. North America 5.2.1. Market Estimates and Forecasts, by Clinical Trial Phase 5.2.2. Market Estimates and Forecasts, by Type of Service Provider 5.3. Europe 5.3.1. Market Estimates and Forecasts, by Clinical Trial Phase 5.3.2. Market Estimates and Forecasts, by Type of Service Provider 5.4. Asia Pacific 5.4.1. Market Estimates and Forecasts, by Clinical Trial Phase 5.4.2. Market Estimates and Forecasts, by Type of Service Provider 5.5.3. Market Estimates and Forecasts, by Clinical Trial Phase 5.5.4. Market Estimates and Forecasts, by Type of Service Provider Chapter 6. Competitive Landscape 6.1 Accenture Plc. 6.1.1 Company Overview 6.1.2 Financial Performance 6.1.3 Product Benchmarking 6.1.4 Strategic Initiatives 6.2 Boehringer Ingelheim GmbH 6.2.1 Company Overview 6.2.2 Financial Performance 6.2.3 Product Benchmarking 6.2.4 Strategic Initiatives 6.3 Bristol-Myers Squibb 6.3.1 Company Overview 6.3.2 Financial Performance 6.3.3 Product Benchmarking 6.3.4 Strategic Initiatives 6.4 Clinquest Group B.V. 6.4.1 Company Overview 6.4.2 Financial Performance 6.4.3 Product Benchmarking 6.4.4 Strategic Initiatives Follow Us:

  6. Your Catalyst To a Lucrative Business 6.5 Cognizant Technology Solutions Corporation 6.5.1 Company Overview 6.5.2 Financial Performance 6.5.3 Product Benchmarking 6.5.4 Strategic Initiatives 6.6 Covance, Inc. 6.6.1 Company Overview 6.6.2 Financial Performance 6.6.3 Product Benchmarking 6.6.4 Strategic Initiatives 6.7 F. Hoffmann-La Roche Ltd 6.7.1 Company Overview 6.7.2 Financial Performance 6.7.3 Product Benchmarking 6.7.4 Strategic Initiatives 6.8 GlaxoSmithKline (GSK) 6.8.1 Company Overview 6.8.2 Financial Performance 6.8.3 Product Benchmarking 6.8.4 Strategic Initiatives 6.9 IBM Corporation 6.9.1 Company Overview 6.9.2 Financial Performance 6.9.3 Product Benchmarking 6.9.4 Strategic Initiatives 6.10 ICON, Plc 6.10.1 Company Overview 6.10.2 Financial Performance 6.10.3 Product Benchmarking 6.10.4 Strategic Initiatives 6.11 iGATE Corporation 6.11.1 Company Overview 6.11.2 Financial Performance 6.11.3 Product Benchmarking 6.11.4 Strategic Initiatives 6.12 iMEDGlobal Corporation Follow Us:

  7. Your Catalyst To a Lucrative Business 6.12.1 Company Overview 6.12.2 Financial Performance 6.12.3 Product Benchmarking 6.12.4 Strategic Initiatives 6.13 Infosys 6.13.1 Company Overview 6.13.2 Financial Performance 6.13.3 Product Benchmarking 6.13.4 Strategic Initiatives 6.14 Ipca Laboratories Ltd 6.14.1 Company Overview 6.14.2 Financial Performance 6.14.3 Product Benchmarking 6.14.4 Strategic Initiatives 6.15 Janssen Research & Development, LLC 6.15.1 Company Overview 6.15.2 Financial Performance 6.15.3 Product Benchmarking 6.15.4 Strategic Initiatives 6.16 Novartis International AG 6.16.1 Company Overview 6.16.2 Financial Performance 6.16.3 Product Benchmarking 6.16.4 Strategic Initiatives 6.17 PAREXEL International Corporation 6.17.1 Company Overview 6.17.2 Financial Performance 6.17.3 Product Benchmarking 6.17.4 Strategic Initiatives 6.18 Pfizer, Inc. 6.18.1 Company Overview 6.18.2 Financial Performance 6.18.3 Product Benchmarking 6.18.4 Strategic Initiatives 6.19 Pharmaceutical Product Development, Inc. (PPD, Inc.) 6.19.1 Company Overview Follow Us:

  8. Your Catalyst To a Lucrative Business 6.19.2 Financial Performance 6.19.3 Product Benchmarking 6.19.4 Strategic Initiatives 6.20 Sanofi Aventis 6.20.1 Company Overview 6.20.2 Financial Performance 6.20.3 Product Benchmarking 6.20.4 Strategic Initiatives 6.21 Synowlwedge LLC 6.21.1 Company Overview 6.21.2 Financial Performance 6.21.3 Product Benchmarking 6.21.4 Strategic Initiatives 6.22 Wipro Ltd. 6.22.1 Company Overview 6.22.2 Financial Performance 6.22.3 Product Benchmarking 6.22.4 Strategic Initiatives 6.23 PRA Health Sciences Inc. 6.23.1 Company Overview 6.23.2 Financial Performance 6.23.3 Product Benchmarking 6.23.4 Strategic Initiatives 6.24 Quantum Solutions India 6.24.1 Company Overview 6.24.2 Financial Performance 6.24.3 Product Benchmarking 6.24.4 Strategic Initiatives 6.25 Quintiles Transnational Corporation 6.25.1 Company Overview 6.25.2 Financial Performance 6.25.3 Product Benchmarking 6.25.4 Strategic Initiatives 6.26 inVentiv Health Inc. 6.26.1 Company Overview 6.26.2 Financial Performance Follow Us:

  9. Your Catalyst To a Lucrative Business 6.26.3 Product Benchmarking 6.26.4 Strategic Initiatives 6.27 OptumInsight, Inc. 6.27.1 Company Overview 6.27.2 Financial Performance 6.27.3 Product Benchmarking 6.27.4 Strategic Initiatives 6.28 United BioSource Corporation 6.28.1 Company Overview 6.28.2 Financial Performance 6.28.3 Product Benchmarking 6.28.4 Strategic Initiatives 6.29 Ecron Acunova 6.29.1 Company Overview 6.29.2 Financial Performance 6.29.3 Product Benchmarking 6.29.4 Strategic Initiatives 6.30 Fortitude Clinical 6.30.1 Company Overview 6.30.2 Financial Performance 6.30.3 Product Benchmarking 6.30.4 Strategic Initiatives 6.31 ITClinical 6.31.1 Company Overview 6.31.2 Financial Performance 6.31.3 Product Benchmarking 6.31.4 Strategic Initiatives Chapter 7. Methodology and Scope 7.1. Research Methodology 7.2. Research Scope & Assumption 7.3. List of Data Sources Follow Us:

  10. Your Catalyst To a Lucrative Business About Us: Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Us: Ryan Shaw Hexa Research Felton Office Plaza 6265 Highway 9 Felton, California 95018 United States Phone: +1-800-489-3075 Email: sales@hexaresearch.com Website - http://www.hexaresearch.com/ Visit Our Blog - hexaresearch1.blogspot.com Follow Us:

More Related